Genomic Valley Biotech Share Price Today

Genomic Valley Biotech acquirers file draft open offer at ₹30 per share

Acquirers Pankaj Grover and Abhisek Gupta filed a draft open offer for up to 26% equity in Genomic Valley Biotech. The offer price is set at ₹30 per share, exceeding the 60-day VWAP of ₹29.62. Total consideration for the open offer is ₹2.38 crore, funded entirely from the acquirers' own resources. The underlying promoter sale involved 46.06% of shares for ₹4.22 crore, triggering the mandatory open offer.

Genomic Valley Biotech Q2FY27 Results: Zero revenue, net loss of ₹1.98 lakh

Genomic Valley Biotech reported zero revenue for Q2FY27, resulting in a net loss of ₹1.98 lakh. Half-year revenue dropped to ₹3.80 lakh from ₹18.00 lakh in H1FY26, driving a net loss of ₹51,569. Cash and cash equivalents fell sharply to ₹3,626 as on September 30, 2026, from ₹42,936 at FY26 end. Positive operating cash flow of ₹1.93 lakh in H1FY27 was driven by working capital changes, not operational profits.

Genomic Valley Biotech promoter sells 46% stake, triggers open offer

Open offer for 7,94,170 shares at ₹30 per share triggered after 46.06% stake acquisition. Detailed Public Statement published in English, Hindi, and Marathi newspapers on October 27, 2026. Acquirers Pankaj Grover and Abhisek Gupta funded transaction entirely from own sources without bank borrowings. Existing promoter Yogesh Agrawal sold 14,07,000 shares for total consideration of ₹4.22 crore.

Genomic Valley Biotech AGM postponed to Dec 2026 after ROC approval

Genomic Valley Biotech AGM deadline extended to December 31, 2026. ROC Haryana granted three-month extension citing promoter health issues. Original statutory deadline was September 30, 2026 under Companies Act. Company advised by ROC to ensure future compliance with statutory norms.

Genomic Valley Biotech returns to profitability in FY26

Genomic Valley Biotech Limited returned to profitability in FY26 with a net profit of ₹3,03,041, reversing a net loss of ₹35,60,932 in the previous year. The turnaround was driven by a reduction in total expenses to ₹22,74,590, despite revenue from operations falling to ₹26,75,000 from ₹84,39,394. For the quarter ended March 31, 2026, the company reported a net loss of ₹81,745 on revenue of ₹3,75,000. The Board appointed Mr. Navjyoti Kumar Jha as Internal Auditor for FY27.

Genomic Valley Biotech Board Meeting Scheduled on May 29, 2026 to Approve Q4FY26 Financial Results

Genomic Valley Biotech Limited has intimated BSE of a board meeting scheduled for May 29, 2026, to consider and approve the audited standalone financial results for the quarter and year ended March 31, 2026. The filing, dated May 18, 2026, was made under Regulation 29 of SEBI (LODR) Regulations, 2015. The trading window for designated persons remains closed from April 01, 2026 until 48 hours after the results are made public on May 29, 2026, in compliance with SEBI's insider trading regulations.